Skip to main content
Gilead, Goldfinch collaborate on kidney disease R&D

Gilead Sciences and Goldfinch Bio signed a multiyear deal that aims to research, develop and market new therapies for orphan and diabetic kidney diseases, with targets coming from Goldfinch's proprietary Kidney Genome Atlas. The agreement could generate more than $2 billion for Goldfinch.

Full Story: